COSCIENS Biopharma Inc. (CSCID)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3.5M 7M 10.5M Q1 '24: 6.6M Q2 '24: 7.6M Q3 '24: 7.5M Q4 '24: 9.6M Q1 '25: 9M Q2 '25: 9.4M Q3 '25: 9.1M Q4 '25: 7.5M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Gross Profit TTM

0 2M 4M 6M Q1 '24: 2.7M Q2 '24: 2.7M Q3 '24: 2.8M Q4 '24: 4.7M Q1 '25: 4.3M Q2 '25: 4.4M Q3 '25: 4.1M Q4 '25: 2.6M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income TTM

-21M -14M -7M 0 7M 14M 21M Q1 '24: -6.1M Q2 '24: -8.7M Q3 '24: -13.9M Q4 '24: -18.3M Q1 '25: -20.1M Q2 '25: -18.7M Q3 '25: -14.7M Q4 '25: -10.7M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q1 '24: -631K Q2 '24: -1.2M Q3 '24: -6.2M Q4 '24: -15.3M Q1 '25: -17.6M Q2 '25: -18.8M Q3 '25: -14.9M Q4 '25: -10.4M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Cost of Revenue TTM

0 2M 4M 6M Q1 '24: 4M Q2 '24: 4.9M Q3 '24: 4.7M Q4 '24: 4.9M Q1 '25: 4.8M Q2 '25: 5M Q3 '25: 5M Q4 '25: 4.9M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q1 '24: -901K Q2 '24: -1.5M Q3 '24: -9.4M Q4 '24: -14.5M Q1 '25: -14M Q2 '25: -17.1M Q3 '25: -10M Q4 '25: -8.5M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q1 '24: -2.2M Q2 '24: -2.8M Q3 '24: -10.8M Q4 '24: -15.7M Q1 '25: -15.3M Q2 '25: -18.2M Q3 '25: -11M Q4 '25: -9.2M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 1.5M 3M 4.5M Q2 '23: 1.8M Q3 '23: 1.8M Q1 '24: 1.8M Q2 '24: 2.2M Q3 '24: 3.1M Q1 '25: 3.1M Q2 '25: 3.2M Q3 '25: 3.2M Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '22: -0.66 Q2 '22: -1.10 Q3 '22: -2.20 Q4 '24: -5.60 Q1 '25: -6.00 Q2 '25: -6.21 Q3 '25: -4.93 Q4 '25: -3.26 Q1 '22 Q2 '22 Q3 '22 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.